Pharmaceutical products carry direct health risks. A mislabelled dosage, a faulty blister pack seal, or contaminated packaging can endanger patients. Regulatory bodies such as the FDA and EMA enforce strict cGMP standards that require documented quality sampling at every stage.
AQL levels in pharma typically range from 0.065 for critical defects to 0.65 for minor cosmetic issues. This means even a single critical defect in a large batch can trigger a full lot rejection, protecting public health.
| Defect Type | AQL | Inspection Level | Notes |
|---|---|---|---|
| Critical (seal integrity, contamination) | 0.065 | Special S-4 | Zero tolerance in most protocols |
| Major (wrong label, missing info) | 0.15 | General II | Regulatory recall risk |
| Minor (cosmetic print shift) | 0.65 | General I | Acceptable if no safety impact |
A batch of 50,000 blister packs had micro-perforations in the foil seal. Without AQL 0.065 inspection, the compromised moisture barrier would have degraded the active ingredient, rendering the medication ineffective.
Pre-shipment inspection at AQL 0.15 detected that 2% of cartons had the wrong dosage printed. The lot was held and relabelled before reaching pharmacies, avoiding a costly recall.
A manufacturer skipped incoming material inspection. Contaminated raw packaging entered production, resulting in a Class II FDA recall affecting 200,000 units and costing over $4 million.
